Kit for immunological detection of TNF-alpha, sTNFR1 and IL-8 in prostate cancer
AssigneeHealth Research, Inc.
InventorsKailash Chadha, Willie Underwood, Austin Miller
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of using biomarkers to improve diagnosis of forms of prostate. The method includes testing a biological sample from an individual for a interleukin-8 (IL-8), Tumor necrosis factor alpha (TNF-α) and soluble tumor necrosis factor-α receptor 1 (sTNFR1), and may further include testing for prostate serum antigen (PSA). Use of these markers in combination provides tests that are more sensitive and specific than PSA in differentiating benign versus malignant prostate disease and/or localized CaP versus metastatic CaP and show that the specificity and sensitivity of a PSA-based CaP diagnosis can be significantly enhanced by measuring IL-8, TNF-α and sTNFR1.
Claims3
A kit for use in immunological detection of tumor necrosis factor α(TNFα), soluble TNF receptor 1 (sTNFR1), interleukin-8 (IL-8), and Prostate Serum Antigen (PSA), wherein the kit comprises one or more sealed containers that comprise monoclonal and/or polyclonal capture antibodies that are specific for TNFα, sTNFR1, IL-8, and PSA, and wherein the kit comprises one or more sealed containers that comprise monoclonal and/or polyclonal detection antibodies that are for use in specifically binding to captured TNFα, sTNFR1, IL-8, and PSA.
Dependencies are inferred from the claim text.